IL10 and amyotrophic lateral sclerosis: In a pilot study, administration of AJ3 significantly increased interleukin-10 (IL-10) and reduced interferon-gamma (IFN-γ) levels, as ALS patients show high levels of IFN-γ from immune cells, contributing to immune-related issues.